Doctor Evidence is supporting IBM Watson’s Discovery Advisor with high quality data for the mining of trends and breakthrough insights in cardiology and oncology realms. Sandra Zelman Lewis, PhD, Chief Guidelines Officer of Doctor Evidence, will present a poster on this collaboration at the 8th Annual Conference on the Science of Dissemination and Implementation, December 14-15, 2015 in Washington, DC. The poster, co-authored by Robert Battista, MBA, CEO and co-founder of Doctor Evidence, is entitled IBM Watson Mega Analytical Database Supports Healthcare Solutions for Personal and Population Health. This conference is co-hosted by AcademyHealth and the National Institutes of Health (NIH). For more information and registration, visit the conference website at http://www.academyhealth.org/Events/events.cfm?ItemNumber=13518. Refer to http://www-03.ibm.com/press/us/en/pressrelease/47031.wss for more information on the Doctor Evidence/IBM Watson collaboration.
IBM Watson mega analytical database supports healthcare solutions for personal and Population health
Sandra Zelman Lewis PhD, Doctor Evidence, Northbrook, IL and Robert Battista, Doctor Evidence, Santa Monica, CA
Background: Ninety percent of current data has been produced in the past 2 years. This pace is accelerating: medical data is expected to double every 73 days by 2020.
This proliferation of clinical data has the potential to support patients and their physicians with knowledge of how various treatment options could provide benefits or result in harms for patients with their unique set of characteristics, support adverse events surveillance and risk mitigation strategies, and monitor disease outbreaks in real time.
Methods: The enormous IBM Watson database already contains more than 15 million pages of medical content, including over 200 medical textbooks and 300 medical journals and content from partners including medical professional societies and government agencies. The evidence-based SaaS company, Doctor Evidence (DRE), is now contributing 2 million additional data points from pee-reviewed articles, clinical research studies, conference proceedings, epidemiology statistics, and drug label data from the US and Europe.
Findings: Watson’s Discovery Advisor integrates data from these disparate sources, including DRE, to ferret out patterns and trends leading to breakthrough insights. Watson for Oncology analyzes individual patients’ data in relation to the vast datasets of personal and aggregated information to help advise on treatment plans based on the clinical expertise of physicians from Memorial Sloan Kettering Cancer Center. This employs structured EMR data and unstructured information from notes and other sources written in plain English. The computer ranks treatment plans and provides supporting evidence from the DRE-curated research studies.
Implications for D&I Research: The D&I field can advance quality and health outcomes through exploration of the vast Watson Ecosystem. Application developers working in cardiovascular or oncology should use the data and processing capabilities to develop health solutions such as clinical decision support (CDS) tools for personalized medicine. The power of Watson’s computing will accommodate patients with multiple morbidities, long a barrier for most CDS. These tools can produce subgroup analyses to address benefits and harms for individual patients with matching characteristics. They can monitor for adverse events, detecting signals earlier. Implementation apps can identify discrepancies in outcomes between recommended care and real patient treatment patterns. The unique Watson/DRE resource can support innovative cutting-edge D&I applications.
Title: IBM Watson mega analytical database supports healthcare solutions for personal and population health
Preferred Presentation Format Podium or Poster
Presentation Agreement: Yes
Complete Data: Yes
Primary Funding Source: No Funding Source
Other Funding: IBM Watson and Doctor Evidence have entered an agreement for data sharing
First Presenting Author
Sandra Zelman Lewis, PhD
Membership Number: 223877
Chief Guidelines Officer
3948 Raintree Ln
Northbrook IL 60062
Second Presenting Author
CEO and co-founder
301 Arizona Ave STE 301
Santa Monica CA 90401